News

Vedevax Block Vaccine finalist for the Empretec Award

The world’s first targeted vaccine against the Bovine Viral Diarrhea Virus (BVDV), developed by Bioinnovo, was one of 4 finalists in its category among around 1,000 projects submitted at the 13th edition of the Pioneering Solutions Contest from Banco Nación, aimed at SMEs and enterprises….

BVDV, immunosuppression, and its impact on cattle herds

Knowledge about the impact of this virus on production and control measures to mitigate its effect on the herd was disseminated at the Second International Congress on Bovine Viral Diarrhea Virus (BVDV), convened by Bioinnovo and INTA. The Second International BVDV Congress, held virtually by…

Innovation in Veterinary Vaccines

Bioinnovo has participated in 2021 ISV Annual Virtual Congress by sharing experiences in the development of innovative veterinary vaccines to fight against several diseases, and by introducing the successful case of Vedevax Block, the first subunit recombinant vaccine in the world that has been approved…

BVDV Differential Diagnosis and Management Strategies

The Workshop “BVDV Differential Diagnosis and Management Strategies” took place as part of the first International Congress on BVDV. Bioinnovo, the first public-private company created by Vetanco and the National Institute of Agricultural Technology (INTA), aimed at investigating, designing and developing IgY antibodies and recombinant vaccines, and at…

First day of the BVDV International Congress

On Monday, July 12 the International Congress of Bovine Viral Diarrhea Virus (BVDV) was initiated addressing the problems raised by the disease in cattle as well as its enormous economic losses and alternatives for its control. Bioinnovo, the public-private company formed by Vetanco and INTA, has organized the First International Congress…